Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Gross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Other Gross PP&E Adjustments (2016 - 2026)

Amphastar Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 13 years, most recently at $568.6 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 9.99% year-over-year to $568.6 million; the TTM value through Dec 2025 reached $568.6 million, up 9.99%, while the annual FY2025 figure was $568.6 million, 9.99% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $568.6 million at Amphastar Pharmaceuticals, down from $606.7 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $606.7 million in Q3 2025 and troughed at $409.8 million in Q3 2021.
  • A 5-year average of $492.5 million and a median of $485.2 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: fell 5.26% in 2022 and later grew 15.42% in 2025.
  • Year by year, Other Gross PP&E Adjustments stood at $438.6 million in 2021, then grew by 3.13% to $452.3 million in 2022, then rose by 15.4% to $522.0 million in 2023, then decreased by 0.97% to $517.0 million in 2024, then increased by 9.99% to $568.6 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for AMPH at $568.6 million in Q4 2025, $606.7 million in Q3 2025, and $556.5 million in Q2 2025.